Effect of Dapagliflozin on Non-proliferative Diabetic Retinopathy in Type 2 Diabetes Mellitus
Objective:To investigate the effect of Dapagliflozin on non-proliferative diabetic retinopathy(NPDR)in type 2 diabetes mellitus.Method:A total of 88 NPDR patients in type 2 diabetes mellitus treated in Xiangdong Hospital Affiliated to Hunan Normal University from October 2021 to June 2023 were selected.They were randomly divided into observation group and control group,44 cases in each group.Both groups were given routine hypoglycemic treatment,and observation group was given Dapagliflozin treatment.Blood glucose indexes and related indexes were compared between the two groups before and after treatment.The correlation between vascular endothelial growth factor(VEGF)and blood glucose fluctuation index was analyzed.Result:After treatment,fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PBG),glycosylated hemoglobin(HbA1c),standard deviation of blood glucose(SDBG),postprandial glucose excursion(PPGE)and large amplitude glycemic excursion(LAGE)all decreased,SDBG,PPGE and LAGE in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,VEGF and macular fovea thickness decreased,and the best-corrected visual acuity(BCVA)increased in both groups,VEGF and macular fovea thickness in observation group were lower than those in control group,and BCVA was higher than that in control group,the differences were statistically significant(P<0.05).Pearson correlation analysis showed that VEGF was positively correlated with SDBG,PPGE and LAGE(P<0.05).Conclusion:Dapagliflozin can improve blood glucose fluctuation,reduce VEGF level,and has a protective effect on NPDR in type 2 diabetes.
Sodium-dependent glucose transporters 2 inhibitorsDapagliflozinNon-proliferative diabetic retinopathy in type 2 diabetes mellitusBlood glucose fluctuationVascular endothelial growth factor
国家科技期刊平台
NSTL
万方数据
